tbuckley/cabot-search huggingface dataset:
Comparación de los sitios en Internet de las Redes de vigilancia de enfermedades en la Unión Europea
Authors: A Lenglet, G Hernández Pezzi
Journal: Eurosurveillance (2006)

En la Union Europea (UE), hoy en dia, la vigilancia de las enfermedades infecciosas se lleva a cabo por la Red Basica de Vigilancia ( Basic Surveillance Network ,BSN) y por otras redes de vigilancia especificas (disease specific surveillance networks, DSN). Cada red tiene su sitio en Internet. El objetivo del informe siguiente es describir las informaciones presentadas en acceso publico en cada sitio de Internet, desde el punto de vista de su utilidad para la vigilancia de un estado miembro de la UE. Se incluyeron en el estudio el BSN y los DSN mencionados en la Decision Comunitaria 2003/542/CE. Se examino y evaluo cada sitio, tomando en cuenta tres categorias principales : 1) las informaciones generales, 2) los procedimientos de recogida de datos y 3) la presentacion de los datos. Se visitaron los sitios en la semana del 5 de Diciembre 2005, siendo analizados diez sitios de redes de vigilancia por ese procedimiento. El 80% de ellos incluyeron la lista de los paises participantes, las direcciones del coordinador de la red, los participantes en cada pais y los objetivos de la red. Una sola red especifica la fuente y la cobertura de los datos por pais y siete de ellas presentan la definicion de caso de la enfermedad vigilada. Los datos crudos estan disponibles en ocho sitios y solamente dos redes incluyeron la presentacion de datos elaborados para toda Europa. Cuatro redes no proporcionan su informe en la pagina web. La periodicidad de las presentaciones, sean datos crudos o elaborados, es muy variable. 
Tambien son heterogeneas las informaciones accesibles al publico en los diez sitios de redes estudiados. Recomendamos que todas las redes presenten en su sitio un conjunto de caracteristicas basicas, incluyendo las definiciones de caso, los procedimientos utilizados para recoger los datos, y los informes periodicos que presentan los datos elaborados para toda la Union Europea.
Someone's Son
Authors: Adam E. Mikolajczyk
Journal: Annals of Internal Medicine (2017)

Ad Libitum3 October 2017Someone's SonAdam E. Mikolajczyk, MDAdam E. Mikolajczyk, MDFrom The University of Chicago Medicine, Chicago, Illinois.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-1267 Audio Reading - “Someone's Son” Audio. Listen to Dr. Virginia Hood read "Someone's Son" by Adam E. Mikolajczyk Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The look in his eyes isstartlinglyfamiliar.Like my son'sin the wake of an unexpected fallstunnedvulnerabledesperate for a comforting embrace.The scars on his arms arehauntinglyjarring.A stained mapof toxic mistakes.But,this skin was oncesoft as powdered snowwithout blemishlike my baby boy's.The parent in mesilentlyweepsThis young patienttoois someone's son. Author, Article, and Disclosure InformationAffiliations: From The University of Chicago Medicine, Chicago, Illinois.Current Author Address: Adam E. Mikolajczyk, MD, The University of Chicago Medicine, Center for Liver Diseases, 5841 South Maryland Avenue MC 4076, M421, Chicago, IL 60637; e-mail, adam.[email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “Someone's Son” Audio. Listen to Dr. Virginia Hood read "Someone's Son" by Adam E. Mikolajczyk Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 3 October 2017Volume 167, Issue 7Page: 518 ePublished: 3 October 2017 Issue Published: 3 October 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Targeting of human cancers by miRNAs delivered by mesenchymal stem cell derived microparticles.
Authors: Agamemnon A. Epenetos, Marianna Prokopi, Costas Pitsillides
Journal: Journal of Clinical Oncology (2017)

e14062 Background: Recent data has shown that several oncogenic and tumor suppressor kinases that are deregulated in human cancers can be targeted via specific miRNA sequences. miRNAs can inhibit oncogenic kinase activity as well as upregulate tumor suppressor kinases in cancer cells, leading to inhibition of tumor processes such as invasion, migration and resistance to apoptosis. Examples include the inhibition of PLK1 activity that is overexpressed in breast, ovarian, pancreatic and colorectal cancers by the ectopic expression of miR-10b, miR-100 or miR-593, and the targeting of the increased FAK expression in breast cancer cells by miR-7. Methods: In this study, we have employed preclinical models of cancer disease and have utilized advanced genomics technologies in combination with innovative in vivo imaging techniques to conduct pharmacokinetics and pharmacodynamics studies as well as safety and efficacy studies in order to establish a mechanism of action and demonstrate that miRNA-loaded microparticles can interfere with tumor promoting kinase activity in vivo Results: Our results demonstrate that delivering specific miRNAs targeted against aberrant protein kinase activity may potentially be a novel approach to selectively inhibit cancer cell processes. Conclusions: We report the development of a new microRNA-based approach to target cancer cells by potentially interfering in multiple signaling pathways that are mediated by kinase-dependent mechanisms. We propose that therapeutic miRNA sequences can be delivered to cancer cells via microparticles (MPs) derived from umbilical cord mesenchymal stem cells (MSCs). The engineered MPs home selectively to tumor sites via specific chemokine receptors, fuse with the cell membrane and incorporate miRNA directly into the target cancer cells.
Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015
Authors: Susan Jin, Richard Pazdur, Rajeshwari Sridhara
Journal: Journal of Clinical Oncology (2017)

Clinical trial eligibility criteria are necessary to define the patient population under study and improve trial safety. However, there are concerns that eligibility criteria for cancer clinical trials are too restrictive and limit patient enrollment in clinical trials. Recently, there have been initiatives to re-examine and modernize eligibility criteria for oncology clinical trials. To assess current eligibility requirements for cancer clinical trials, we have conducted a comprehensive review of eligibility criteria for commercial investigational new drug clinical trial applications submitted to the US Food and Drug Administration Office of Hematology and Oncology Products in 2015. Our findings suggest that eligibility criteria for current cancer clinical trials tend to narrowly define the study population and limit the study to lower-risk patients, which may not be reflective of the greater patient population outside of the study. We discuss potential areas for expanding eligibility criteria to include more patients in clinical trials and design options for clinical trials incorporating expanded eligibility criteria. The broadening of clinical trial eligibility criteria can be considered to better reflect the real-world patient population, improve clinical trial participation, and increase patient access to new investigational treatments.
Statistical considerations and challenges for immuno-oncology biomarker studies.
Authors: Lin Li, Sandra L. Close, Christina M. Bromley, Fang Chen, Laura B. Gillis
Journal: Journal of Clinical Oncology (2016)

e14500 Background: Subgroups including long term survivors or those with delayed clinical effect characterize immuno-oncology studies (IO). Consequently, IO studies need to identify subgroups of responders, even more critical in the era of combination therapies. A significant challenge is appropriate design and power of studies to identify biomarker defined subgroups, even if nested in the overall efficacy trial. Methods: Simulation studies modeling clinical characteristics, treatment response, survival time, and biomarker characteristics can be utilized to evaluate designs and power to detect biomarkers. These studies inform which characteristics to investigate, impact of trial factors, and appropriate type I error adjustments. Simulations under a variety of clinical scenarios for one and two arm studies to detect a predictive biomarker alone and in conjunction with another biomarker such as PD-L1 were completed. Results: Scenarios for a range of survival times (3 to 60 months), hazard ratios (HR: 1.25 to 4.0), subgroup sizes (20% to 80%), and censoring rates (coupled to duration of study) were performed using survival models. The simulations resulted in a study with as few as 67 subjects required for a one-arm study with biomarker HR of 0.3, biomarker subgroup size of 10%, but needing 90% of events to have occurred for 80% power. Additional scenarios incorporating longer survival, delayed clinical effect, and cross-over designs were simulated and will be presented demonstrating the effect of correction or not for study characteristics. Conclusions: The impact of study designs, statistical methods and assumptions, and the range of sample sizes required to detect predictive biomarkers will be presented reinforcing the importance of a priori design and biomarker strategies tailored for IO. Practical solutions for a successful IO biomarker study will be presented.
Gene alteration in triple negative breast cancer patients in a phase I/II study of combination therapy with eribulin and olaparib
Authors: A. Shimomura, K. Yonemori, N. Masuda, K. Aogi, M. Takahashi, Y. Naito, S. Shimizu, R. Nakamura, A. Hamada, H. Michimae, J. Hashimoto, H. Yamamoto, C. Shimizu, K. Tamura, Y. Fujiwara
Journal: Annals of Oncology (2017)
Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus
Authors: Yusuke Sato, Hideki Matsui, Naoki Yamamoto, Risa Sato, Tsubasa Munakata, Michinori Kohara, Hideyoshi Harashima
Journal: Journal of Controlled Release (2017)
Characteristics of Novel Therapeutics and Postmarket Safety Events—Reply
Authors: Nicholas S. Downing, Nilay D. Shah, Joseph S. Ross
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PREDMED® TEST, new normalized expression method to predict the effect of tumor- and microenvironment-targeted therapies
Authors: J. Fritz, L. Verlingue, J. Schmidt, M. Baranger, C. Gianesini, M. Schaeffer, D. Malka, J.Y. Scoazec, B. Loubaton, D. Bagnard
Journal: Annals of Oncology (2017)
Junior doctor is struck off after trying to arrange sex with minor
Authors: Clare Dyer
Journal: BMJ (2017)

A junior doctor has been struck off after he used a gay dating app to arrange sex with an undercover policeman posing as a 13 year old boy.

Thomas Jenkins, 28, a foundation year 2 doctor in psychiatry, was convicted of inciting a boy aged 13 to 15 to engage in penetrative sexual activity.

In April, after pleading guilty at Manchester Crown Court, he was sentenced to participate in a sexual offenders’ programme for three years and to be on the sex offenders’ register for five years.

Jenkins …
Abstract 16128: Keep Your Heart Healthy: A Community-based Collaboration Shows Progress Toward Ideal Cardiovascular Health in Underserved Chicago Communities
Authors: Stephen Havas, Rabih Dahdouh, Hongyan Ning, Berenice Tow
Journal: Circulation (2016)

Introduction: AHA’s Life’s Simple 7 (LS7) is an easy guide toward achieving ideal cardiovascular health. However, few large-scale projects have assessed whether the AHA LS7 can have a significant i...
Single-cell combined mutation and gene expression studies of circulating tumor-associated cells in non-small cell lung cancer
Authors: J. Mong, J. Shi, T.M. Chin, S-W. Wong, A. Tee, D. Chan, K. Wong, S. Yeap, L. Ngo, Y-O. Tan, M. Hu, J. Ying, M-H. Tan
Journal: Annals of Oncology (2017)
Cost effectiveness of treating endemic Burkitt lymphoma in Uganda.
Authors: Avram Denburg
Journal: Journal of Clinical Oncology (2017)

e18339 Background: Despite high cure rates achieved in high-income countries, outcomes for children with Burkitt lymphoma (BL) in most low- and middle-income countries (LMICs) remain suboptimal. Perceptions of high cost and resource intensity remain political barriers to the prioritization of BL and other childhood cancer treatment programs in many LMIC health systems. Little to no knowledge exists of the actual cost and cost-effectiveness of treating paediatric cancers in LMICs. To improve outcomes for children with BL, the Uganda Cancer Institute implemented a comprehensive BL treatment program in 2012. Drawing on centralized patient-level data, we undertook an economic evaluation of the program to ascertain the cost-effectiveness of BL therapy in a specific LIC setting. Methods: We compared the treatment of BL (local standard) to usual care (no care), in a cohort of 215 patients treated between 2012 and 2015. Costs included direct, indirect healthcare, and indirect patient costs. Our primary measure of effectivenesswas overall survival (OS). Patient outcomes were determined through electronic chart abstraction. The cost per DALY averted was calculated using WHO-CHOICE methodology and compared to standard definitions of cost-effectiveness. Results: The 2-year OS with treatment was 53% (95% CI, 43% to 62%). Nine percent of patients abandoned therapy. The cost per DALY averted in the treatment group was US$78. Cumulative estimate of national DALYs averted through treatment was 11,046 years, and the total national cost of treatment was US$755,216. The ratio of cost per DALY averted to per capita gross domestic product (GDP) was 0.12, reflecting a very cost-effective intervention. Conclusions: This study demonstrates that treating BL with locally tailored protocols is very cost-effective relative to per capita GDP in Uganda. Studies of this kind will furnish crucial evidence to assist policymakers prioritize the allocation of LMIC health system resources among NCDs, including childhood cancer.
Rapid pathogen-specific phenotypic antibiotic susceptibility testing using digital LAMP quantification in clinical samples
Authors: Nathan G. Schoepp, Travis S. Schlappi, Matthew S. Curtis, Slava S. Butkovich, Shelley Miller, Romney M. Humphries, Rustem F. Ismagilov
Journal: Science Translational Medicine (2017)

Digital ultrafast loop-mediated isothermal amplification determines phenotypic antibiotic susceptibility of Escherichia coli in clinical urine samples in less than 30 min.
Pyramidal Cell-Interneuron Circuit Architecture and Dynamics in Hippocampal Networks
Authors: Daniel Fine English, Sam McKenzie, Talfan Evans, Kanghwan Kim, Euisik Yoon, György Buzsáki
Journal: Neuron (2017)

Excitatory control of inhibitory neurons is poorly understood due to the difficulty of studying synaptic connectivity in vivo. We inferred such connectivity through analysis of spike timing and validated this inference using juxtacellular and optogenetic control of presynaptic spikes in behaving mice. We observed that neighboring CA1 neurons had stronger connections and that superficial pyramidal cells projected more to deep interneurons. Connection probability and strength were skewed, with a minority of highly connected hubs. Divergent presynaptic connections led to synchrony between interneurons. Synchrony of convergent presynaptic inputs boosted postsynaptic drive. Presynaptic firing frequency was read out by postsynaptic neurons through short-term depression and facilitation, with individual pyramidal cells and interneurons displaying a diversity of spike transmission filters. Additionally, spike transmission was strongly modulated by prior spike timing of the postsynaptic cell. These results bridge anatomical structure with physiological function.
Role of circulating miRNAs as prognostic biomarkers in resected early-stage non-small cell lung cancer
Authors: P. Ulivi, E. Petracci, V. Ludovini, G. Marisi, A. Delmonte, N. De Luigi, D. Calistri, L. Crinò, D. Amadori, R. Chiari, S. Baglivo, F. Grignani
Journal: Annals of Oncology (2017)
Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer
Authors: E.N. Pijnappel, R. Klaassen, K.S. van der Lee, M. Pleunis - van Empel, D. Richel, M. Legdeur, A. Nederveen, H.W.M. van Laarhoven, H.W. Wilmink
Journal: Annals of Oncology (2019)
Checkpoint inhibitors in MSI tumors: Lessons from a monocentric experience
Authors: Y. El Dakdouki, L. Verlingue, C. Massard, A. Leary, L. Lacroix, E. Rouleau, J-Y. Scoazec, O. Caron, P. Benusiglio, P. Kannouche, A. Hollebecque, D. Malka, J-C. Soria, A. Marabelle
Journal: Annals of Oncology (2017)
OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC)
Authors: M. Robson, K.J. Ruddy, S-A. Im, E. Senkus-Konefka, B. Xu, S.M. Domchek, N. Masuda, S. Delaloge, W. Li, N. Tung, A. Armstrong, W. Wu, C. Goessl, A. Degboe, P.F. Conte
Journal: Annals of Oncology (2017)
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
Authors: Edward Gane, Eric Lawitz, David Pugatch, Georgios Papatheodoridis, Norbert Bräu, Ashley Brown, Stanislas Pol, Vincent Leroy, Marcello Persico, Christophe Moreno, Massimo Colombo, Eric M. Yoshida, David R. Nelson, Christine Collins, Yang Lei, Matthew Kosloski, Federico J. Mensa
Journal: New England Journal of Medicine (2017)

Chronic hepatitis C virus (HCV) infection is more prevalent among patients who have chronic kidney disease than among those who do not have the disease. Patients with chronic kidney disease who also have HCV infection are at higher risk for progression to end-stage renal disease than those who have chronic kidney disease without HCV infection. Patients with both HCV infection and advanced chronic kidney disease have limited treatment options.We conducted a multicenter, open-label, phase 3 trial to evaluate the efficacy and safety of treatment with the combination of the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults who had HCV genotype 1, 2, 3, 4, 5, or 6 infection and also had compensated liver disease (with or without cirrhosis) with severe renal impairment, dependence on dialysis, or both. Patients had stage 4 or 5 chronic kidney disease and either had received no previous treatment for HCV infection or had received previous treatment with interferon or pegylated interferon, ribavirin, sofosbuvir, or a combination of these medications. The primary end point was a sustained virologic response 12 weeks after the end of treatment.Among the 104 patients enrolled in the trial, 52% had genotype 1 infection, 16% had genotype 2 infection, 11% had genotype 3 infection, 19% had genotype 4 infection, and 2% had genotype 5 or 6 infection. The sustained virologic response rate was 98% (102 of 104 patients; 95% confidence interval, 95 to 100). No patients had virologic failure during treatment, and no patients had a virologic relapse after the end of treatment. Adverse events that were reported in at least 10% of the patients were pruritus, fatigue, and nausea. Serious adverse events were reported in 24% of the patients. Four patients discontinued the trial treatment prematurely because of adverse events; three of these patients had a sustained virologic response.Treatment with glecaprevir and pibrentasvir for 12 weeks resulted in a high rate of sustained virologic response in patients with stage 4 or 5 chronic kidney disease and HCV infection. (Funded by AbbVie; ClinicalTrials.gov number, NCT02651194 .).
Overexpression of toll-like receptor 9 (TLR9) in elderly cancer patients when compared to cancer-free elderly control group
Authors: L. Torres, L.T. Sales, M. Santaliz de Godoy Moreno, C.C. Resende Lira, G. Delgado Soriano, E. Bezerra Cintra, K. Jatahy, M.J.G. Mello, L.C.S. Thuler, J.T. Oliveira Lima
Journal: Annals of Oncology (2017)